Characterization and expression analysis of UBC gene family provide insights into the potential roles in pigment biosynthesis in pepper fruit. [PDF]
Jia L +9 more
europepmc +1 more source
CCT2 Promotes Prostate Cancer Progression Through EIF3F‐Dependent Stabilization of FASN
ABSTRACT Prostate cancer (PCa) is increasingly recognized to be driven by dysregulated lipid metabolism. Although fatty acid synthase (FASN) is highly expressed in PCa, the mechanisms governing FASN protein stability and its functional integration into oncogenic lipid metabolism remain poorly defined.
Shun Xu +13 more
wiley +1 more source
Specificity and recognition of the ADP-ribosyl-ubiquitin modification in the DNA damage response. [PDF]
Chatrin C +14 more
europepmc +1 more source
PDIA6–SCD1 Axis Rewires Lipid Metabolism to Drive Gastric Cancer Progression
Protein disulfide isomerase A6 (PDIA6) is identified as an oncogenic driver in gastric cancer. PDIA6 directly binds and stabilizes SCD1 by limiting its ubiquitin–proteasome‐mediated degradation, thereby sustaining monounsaturated fatty acid (MUFA)‐enriched lipid homeostasis and lipid metabolic reprogramming.
Zhen Tian +13 more
wiley +1 more source
MGRN1 in development and disease: a unifying view of a versatile membrane-tethered E3 ubiquitin ligase. [PDF]
Riglos A, Gunn TM, Kong JH.
europepmc +1 more source
Host‐specific compatibility between RNF138‐like proteins and flavivirus NS5 determines NS5 stability. Mammalian RNF138 but not arthropod homologs recognizes and induces conserved NS5/RdRp K48‐linked ubiquitination and proteasomal degradation, thereby restricting viral replication. Ectopic RNF138 in mice attenuates TBEV‐induced pathogenesis. (Created in
Jialiang Sun +6 more
wiley +1 more source
Ubiquitin-conjugating enzyme membrane anchor Cue1 confers resistance to hygromycin B in <i>Saccharomyces cerevisiae</i>. [PDF]
Avaala JA +7 more
europepmc +1 more source
Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao +11 more
wiley +1 more source

